Potentiation of doxorubicin efficacy in hepatocellular carcinoma by the DNA repair inhibitor DT01 in preclinical models.
Objective: This study aimed to explore the antitumour effect of the DNA repair inhibitor, DT01 (the cholesterol conjugated form of Dbait), as an adjunct treatment to enhance the therapeutic efficacy of transarterial chemoembolization (TACE) in pre-clinical models of hepatocellular carcinoma (HCC).Me...
| Publicado en: | European Radiology Vol. 27; no. 10; pp. 4435 - 4445 |
|---|---|
| Autores principales: | , , , , , , , , |
| Formato: | Journal Article |
| Publicado: |
Springer Nature
Oct2017
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=124912470&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 124912470 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 09387994 NPH jtl: European Radiology issn: 09387994 maglogo: N pubinfo: dt: Oct2017 vid: 27 iid: 10 pid: 237 pub: Springer Nature place: New York, New York artinfo: ui: 124912470 124912470 144008825 NLM28374075 10.1007/s00330-017-4792-1 NLM28374075 124912470 ppf: 4435 ppct: 10 formats: fmt: @attributes: type: P tig: atl: Potentiation of doxorubicin efficacy in hepatocellular carcinoma by the DNA repair inhibitor DT01 in preclinical models. aug: au: Herath, Nirmitha Devun, Flavien Herbette, Aurélie Lienafa, Marie-Christine Chouteau, Philippe Sun, Jian-Sheng Dutreix, Marie Denys, Alban Herath, Nirmitha I Herbette, Aurélie affil: Team Pathophysiology and Therapy of Chronic Viral Hepatitis, Inserm U955 , Université Paris-Est , Créteil France sug: subj: Chemoembolization, Therapeutic Methods Cholesterol Carcinoma, Hepatocellular Therapy DNA Therapeutic Use Antineoplastic Agents Therapeutic Use Liver Neoplasms Therapy DNA Drug Effects Doxorubicin Therapeutic Use Treatment Outcomes Body Weights and Measures Animals Liver Neoplasms DNA Male Carcinoma, Hepatocellular Rabbits Models, Biological Cholesterol Therapeutic Use Scales Male ab: Objective: This study aimed to explore the antitumour effect of the DNA repair inhibitor, DT01 (the cholesterol conjugated form of Dbait), as an adjunct treatment to enhance the therapeutic efficacy of transarterial chemoembolization (TACE) in pre-clinical models of hepatocellular carcinoma (HCC).Methods: A rabbit model bearing liver tumours was either left untreated or treated with TACE or with a combination of TACE+DT01. Tumour growth was monitored by ultrasound. These results were further confirmed in mice grafted with an intrahepatic human HCC model treated with doxorubicin (DOX) alone or DOX+DT01.Results: The combination of DT01 with TACE in a rabbit liver model led to a significant decrease in tumour volume (p=0.03). Colour Doppler and immunohistochemical staining revealed a strong decrease in vascularization in the DT01+TACE-treated group preventing the tumour growth restart observed after TACE alone. Similarly, the DT01 combination with DOX led to significant anti-tumour efficacy compared to DOX alone (p=0.02) in the human HCC model. In addition, a significant decrease in vascularization in the group receiving combination DT01 and DOX treatment was observed.Conclusions: DT01 is well tolerated and may potentiate HCC treatment by enhancing the DNA-damaging and anti-vascularization effect of TACE with doxorubicin.Key Points: • DT01 combined with TACE leads to significant anti-tumour efficacy without additional toxicity. • A potential anti-angiogenic role of DT01 was identified in preclinical models. • DT01 may potentiate HCC treatment by enhancing the efficacy of TACE. pubtype: Academic Journal doctype: Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|